-
ARIAD Announces Initial Clinical Data on Ponatinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Friday, June 3, 2011 - 7:36am | 147ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced initial clinical findings on ponatinib in patients with advanced acute myeloid leukemia. In addition to being an investigational pan-BCR-ABL inhibitor for use in chronic myeloid leukemia, ponatinib selectively and potently inhibits certain...
-
J.P. Morgan Overweight On Gilead Sciences After Meeting With Management
Friday, June 3, 2011 - 7:26am | 288J.P. Morgan Chase & Co. has an Overweight rating and a $45 price target on shares of Gilead Sciences (NASDAQ: GILD). In a note to clients, J.P. Morgan writes, "We recently hosted an investor meeting with Gilead in San Fran with John Milligan (President and COO), Robin Washington (CFO) and...
-
Goldman Sachs Reiterates Hold on Human Genome Sciences
Friday, June 3, 2011 - 7:24am | 111Goldman Sachs reiterated its Hold rating on Human Genome Sciences (NASDAQ: HGSI) after the company launched its new drug Benlysta. In a research report published today, Goldman Sachs states, "The early Benlysta launch appears to be tracking well, but we remain on the sidelines as we believe HGSI...
-
Orexigen Therapeutics Provides a Regulatory Update on Contrave NDA
Friday, June 3, 2011 - 7:03am | 118Orexigen Therapeutics, Inc. (Nasdaq: OREX) announced today that it recently met with the Food and Drug Administration regarding the New Drug Application for Contrave (naltrexone HCl/bupropion HCl) extended-release tablets for the treatment of obesity, including weight loss and maintenance of weight...
-
Bank of America Gears Up For Alexion's Stock Split Aftermath
Friday, June 3, 2011 - 6:11am | 115Bank of America has published a report on Alexion Pharmaceuticals (NASDAQ: ALXN) in response to the company's recent stock split. In the report, Bank of America writes, "We adjusted our PO for the recently completed 2:1 stock split from $110 to $56, which includes minor model adjustments. We...
-
Some stock trading ideas for June 3rd
Thursday, June 2, 2011 - 4:31pm | 2304( click to enlarge ) Sky mobi Ltd (NASDAQ:MOBI) - Technically, there is no reason to take exposure in this stock as there is no evidence of the reversal of the ongoing downward move. However, if the support at $8 holds, a rally towards 9-9.48 could be seen. Only a close above $9.48 will...
-
Cytokinetics Announces Successful Completion of Phase IIA "Evidence of Effect" Clinical Trial of CK-2017357
Thursday, June 2, 2011 - 4:03pm | 111Cytokinetics, Incorporated (NASDAQ: CYTK) announced the successful completion of its Phase IIa "Evidence of Effect" clinical trial of CK-2017357, a fast skeletal muscle activator, in patients with claudication associated with peripheral artery disease in connection with a poster presentation today...
-
Goldman Sachs Initiates Coverage of Incyte Corporation with Neutral and PT of $20
Thursday, June 2, 2011 - 9:33am | 141Goldman Sachs initiated coverage of Incyte Corporation (NASDAQ: INCY) with a Neutral rating and a price target of $20. In a research report published today, Goldman states, "We see INCY as a high-quality story that could potentially have the first- in-class drug ruxolitinib to treat myelofibrosis...
-
Oppenheimer Maintains Outperform Rating On Pluristem Therapeutics
Thursday, June 2, 2011 - 9:18am | 151According to Oppenheimer, Pluristem Therapeutics (NASDAQ: PSTI) Outperform rating is maintained. Oppenheimer said that yesterday, Aastrom Biosciences (ASTM, $3.04, Not Rated) reported top-line results for its Phase II study called RESTORE-CLI. “The trial investigated administration of expanded...
-
UPDATE: Jefferies Raises PT on Cubist Pharmaceuticals
Thursday, June 2, 2011 - 7:44am | 79Jefferies is out with its report today on Cubist Pharmaceuticals (NASDAQ: CBST), raising its PT from $36 to $44. In a note to clients, Jefferies writes, "CBST's CXA-201 is potentially the most potent Gram-negative antibiotic in development (Phase 3 to begin by YE11), particularly for the most...
-
GSK and Theravance Announce Results of Two Pivotal Phase III Studies for Relovair(TM) in COPD
Thursday, June 2, 2011 - 7:04am | 91GlaxoSmithKline (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the results of two pivotal 6-month efficacy and safety phase III studies of Relovair for patients with chronic obstructive pulmonary disease. Results of both studies support the continuation of the Relovair development...
-
Goldman Initiates Dendreon At Buy, $50 PT
Thursday, June 2, 2011 - 6:28am | 25Goldman Sachs has initiated coverage on Dendreon Corporation (NASDAQ: DNDN) with a Buy rating and $50 price target.
-
Goldman Initiates INCY At Neutral, $20 PT
Thursday, June 2, 2011 - 6:27am | 23Goldman Sachs has initiated Incyte Corporation (NASDAQ: INCY) with a Neutral rating and $20 price target.
-
Jefferies Raises PT on Cubist Pharmaceuticals To $44
Thursday, June 2, 2011 - 6:25am | 27Jefferies & Company has raised the price target on Cubist Pharmaceuticals (NASDAQ: CBST) from $36 to $44 and maintains its Buy rating.
-
The Good, The Bad & The Ugly 06-01-2011
Wednesday, June 1, 2011 - 6:51pm | 933Cusick's Corner To say that this was an ugly close is an understatement. Now here's the good and the bad. The good is that the day is over (especially if you were long). The bad is that the market was down (300 on the Dow). This was a solid distribution day with a close below the lows of yesterday...